Globus Medical (GMED) has drawn attention after recent share price moves, prompting investors to look more closely at the valuation and fundamentals of this musculoskeletal-focused medical device company.

Recent trading has been strong, with a 12.24% 1 month share price return and a 39.53% 1 year total shareholder return. This suggests momentum has been building around Globus Medical as investors reassess its growth profile and risk outlook.

If you are comparing Globus Medical with other growth names in healthcare technology, this is a good moment to widen your search using our screener of 35 healthcare AI stocks

With shares up strongly over the past year and trading at a premium to the average analyst price target, the key question now is whether Globus Medical still offers upside or if the market is already pricing in future growth.

Most Popular Narrative: 12% Undervalued

With Globus Medical last closing at $96.82 against a narrative fair value of $110.08, attention is firmly on what is driving that valuation gap.

Successful integration and synergy capture from the NuVasive and Nevro acquisitions are providing opportunities for increased cross selling, cost efficiencies, and realization of deferred tax assets, which are expected to drive margin expansion, boost earnings, and enhance recurring cash flows in upcoming years.

Want to see what is baked into that story? The narrative leans heavily on sustained revenue gains, firm margins, and a richer earnings multiple. The exact assumptions may surprise you.

Result: Fair Value of $110.08 (UNDERVALUED)

However, extended sales cycles for robotic systems and ongoing integration work at Nevro and NuVasive could disrupt revenue timing and margins, putting pressure on that upside narrative.

Another Take: What The Earnings Multiple Is Saying

Those narrative fair value estimates of $110.08 contrast with how the market is pricing earnings today. Globus Medical trades on a P/E of 24.3x versus a fair ratio of 22.4x, even though this is below both peer and US Medical Equipment averages of 46.3x and 26x. Is that a small overpayment for quality, or a thin margin of safety?

Next Steps

Does this story feel too optimistic or too cautious? Take a moment to review the numbers for yourself and see what stands out. Then check the 3 key rewards

Looking for more investment ideas?

If Globus Medical has sharpened your thinking, do not stop here. Broaden your watchlist with other focused ideas that might suit your risk and return preferences.

• Target potential mispricings by scanning companies that look beaten down yet financially sound using the 63 high quality undervalued stocks.
• Build a steadier income stream by checking out businesses with higher yields and resilient payouts through the 13 dividend fortresses.
• Prioritise resilience by focusing on companies with robust finances and low risk profiles using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.